Drug Trial Radar · NCT07249892
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Nov 19, 2025
Primary completion
Jul 30, 2027
Study completion Sep 6, 2027
Sponsor
- Lead sponsor
- Chengdu Syncor Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Beijing Quarkxia Technology Co., Ltd.
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
Conditions
- Metastatic Solid Tumors
Interventions
BPR-6023021 for injectionDrug
BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0Time frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.